share_log

HC Wainwright & Co. Initiates Coverage On Cadrenal Therapeutics With Buy Rating, Announces Price Target of $3

HC Wainwright & Co. Initiates Coverage On Cadrenal Therapeutics With Buy Rating, Announces Price Target of $3

HC Wainwright & Co.以买入评级启动对肾上腺疗法的报道,宣布目标股价为3美元
Benzinga ·  2023/11/20 07:05

HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy rating and announces Price Target of $3.

HC Wainwright & Co. 分析师约瑟夫·潘吉尼斯以买入评级启动了对Cadenal Therapeutics(纳斯达克股票代码:CVKD)的报道,并宣布目标股价为3美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发